Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias-Reference-Cited by-同舟云学术

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

Published:2009-10-20 Issue:1 Volume:49 Page:111-112
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Stagno Fabio,Vigneri Paolo,Fabro Vittorio Del,Stella Stefania,Restuccia Nunzio,Giallongo Cesarina,Massimino Michele,Berretta Salvatore,Pennisi Maria Stella,Tibullo Daniele,Tirrò Elena,Buscarino Calogero,Messina Angelo,Raimondo Francesco Di

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/02841860903302913

Reference5 articles.

1. Will targeted therapy hold its promise? An evidence-based review

2. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

3. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

4. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

5. Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives;Anticancer Research;2020-05

2. Optimal Response in a Patient With CML Expressing BCR–ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report;In Vivo;2020

3. Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform;Anticancer Research;2019-12

4. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice;Genes;2019-09-13

5. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report;Anticancer Research;2019-07